INNOVATE announces MediBeacon received approval for TGFRTM System

INNOVATE announced that MediBeacon, in which INNOVATE owns a 44.7% equity interest, has received approval from the U.S. Food and Drug Administration, FDA, for the next generation MediBeacon TGFRTM System including the latest TGFRTM Reusable Sensor. The TGFR System enables kidney function assessment at the point of care by measuring the clearance rate of Lumitrace, a non-radioactive, non-iodinated fluorescent GFR agent. The TGFR Reusable Sensor placed on the skin measures the change in Lumitrace fluorescence intensity as a function of time.